Catalent, Inc. (NYSE:CTLT) to Post Q4 2024 Earnings of $1.29 Per Share, Zacks Research Forecasts

Catalent, Inc. (NYSE:CTLT – Get Rating) – Equities researchers at Zacks Research raised their Q4 2024 earnings per share estimates for Catalent in a research note issued on Thursday, March 9th. Zacks Research analyst D. Dey now forecasts that the company will post earnings per share of $1.29 for the quarter, up from their previous estimate of $1.28. The consensus estimate for Catalent’s current full-year earnings is $2.84 per share.

Other research analysts have also issued reports about the company. Barclays raised their price target on Catalent from $58.00 to $82.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 8th. Robert W. Baird raised their price target on Catalent from $75.00 to $82.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 8th. Royal Bank of Canada raised their price target on Catalent from $73.00 to $85.00 in a research report on Wednesday, February 8th. Bank of America lifted their target price on Catalent from $60.00 to $78.00 in a report on Wednesday, February 8th. Finally, Morgan Stanley lifted their target price on Catalent from $81.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, February 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.30.

Catalent Trading Down 2.9 %

CTLT opened at $67.92 on Monday. Catalent has a 52 week low of $40.69 and a 52 week high of $115.33. The business has a fifty day simple moving average of $59.93 and a 200-day simple moving average of $62.38. The firm has a market cap of $12.23 billion, a P/E ratio of 30.05, a P/E/G ratio of 3.09 and a beta of 1.18. The company has a quick ratio of 1.38, a current ratio of 1.91 and a debt-to-equity ratio of 0.86.

Catalent (NYSE:CTLT – Get Rating) last issued its quarterly earnings data on Tuesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.64 by ($0.02). The business had revenue of $1.15 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Catalent had a return on equity of 11.40% and a net margin of 8.62%.

Hedge Funds Weigh In On Catalent

Institutional investors have recently added to or reduced their stakes in the stock. Tokio Marine Asset Management Co. Ltd. boosted its holdings in Catalent by 22.5% in the 2nd quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,043 shares of the company’s stock valued at $326,000 after purchasing an additional 558 shares in the last quarter. US Bancorp DE boosted its holdings in Catalent by 1.4% in the 3rd quarter. US Bancorp DE now owns 19,237 shares of the company’s stock valued at $1,392,000 after purchasing an additional 272 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp boosted its holdings in Catalent by 12.0% in the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 90,954 shares of the company’s stock valued at $9,759,000 after purchasing an additional 9,723 shares in the last quarter. Itau Unibanco Holding S.A. boosted its holdings in Catalent by 372.7% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 3,134 shares of the company’s stock valued at $227,000 after purchasing an additional 2,471 shares in the last quarter. Finally, Empirical Finance LLC boosted its holdings in Catalent by 25.0% in the 3rd quarter. Empirical Finance LLC now owns 3,644 shares of the company’s stock valued at $264,000 after purchasing an additional 728 shares in the last quarter. Institutional investors and hedge funds own 99.38% of the company’s stock.

Insider Buying and Selling at Catalent

In other news, insider Ricky Hopson sold 643 shares of Catalent stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $49.36, for a total transaction of $31,738.48. Following the sale, the insider now owns 16,452 shares in the company, valued at $812,070.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.58% of the stock is owned by insiders.

Catalent Company Profile

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.